NasdaqGS:OLMABiotechs
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf
Olema Pharmaceuticals, Inc. recently reported fourth-quarter 2025 results showing a US$46.06 million net loss and a US$162.45 million full-year net loss, alongside a new US$71.82 million shelf registration for common stock tied to an ESOP-related offering.
Despite widening annual losses, the company slightly narrowed its per-share loss, highlighted a US$505.4 million cash position, and continued to advance its breast cancer pipeline with new clinical trials and planned scientific...